A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Kerry Lynn Reynolds, Philippe L. Bedard, Se Hoon Lee, Chia Chi Lin, Josep Tabernero, Maria Alsina, Ezra Cohen, José Baselga, George Blumenschein, Donna M. Graham, Ignacio Garrido-Laguna, Dejan Juric, Sunil Sharma, Ravi Salgia, Abdelkader Seroutou, Xianbin Tian, Rose Fernandez, Alex Morozov, Qing Sheng, Thiruvamoor RamkumarAngela Zubel, Yung Jue Bang

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences